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Introduction. The search for new pleiotropic effects of known active 
pharmaceutical ingredients (APIs) is a current global trend of R&D in the 
pharmaceutical industry. Special attention is paid to APIs from vegetable raw materials 
(eg flavonoids). Thus, hesperidin shows a variety of pharmacological effects and is 
potentially promising for the treatment of neurodegenerative diseases.  
Aim. Study of hesperidin influence on butyrylcholinesterase from human serum 
(BChE). 
Methods. QSAR analysis, molecular docking, ex vivo kinetic study of BChE 
inhibition. 
Results. Hesperidin is widely used in medicines and dietic supplements to 
improve blood flow through vazotreads properties. Literature review and in-house 
QSAR analysis showed that hesperidin also displays the various biological and 
pharmacological properties, including antiinflammatory, antineoplastic, antidepressant 
and antioxidant activity. Molecular docking of hesperidin into the active site of BChE 
allows to assume the existence of the inhibition effect. A spectrophotometric study of 
the kinetics of inhibition BChE from human serum by hesperidin in ex vivo conditions 
showed that for BChE, Ki = 30.50±0.04 μM, IC50 = 450 μM. Analysis of the results 
shows that hesperidin inhibits the enzyme by mixed (partial) mechanism. It is likely 
that hesperidin binds both to the active site of the enzyme, and outside, and enzyme-
substrate complex retains partial activity compared to that of the native enzyme. 
Considering the data obtained and the features of the hesperidin pharmacokinetics 
allows assuming that it is the perspective API for the drugs for the treatment of 
neurodegenerative diseases. 
Conclusions. Hesperidin inhibits the BChE by mixed mechanism. Further 
comprehensive research in this area is relevant with aim of further development of 
drugs for the treatment of neurodegenerative diseases. 
